Pluristem Therapeutics (PSTI) Initiates South Korean Arm of Multinational Phase 2 Intermittent Claudication Trial
7/8/2014 6:09:49 AM
HAIFA, Israel, July 8, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the treatment of intermittent claudication (IC). Patient screening is now underway at three clinical centers, making South Korea the fourth country to participate in this randomized, double-blind, placebo-controlled Phase II trial. The trial has been ongoing at clinical sites in the U.S., Israel and Germany with an enrollment target of 150 patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by